Abstract 12756: Long-Term Efficacy and Safety of Evinacumab in Adult and Adolescent Patients With Homozygous Familial Hypercholesterolemia
Bibliographic record
Abstract
Introduction: Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare genetic lipid disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease, underscoring the need for early and aggressive treatment. Evinacumab, an angiopoietin-like 3 inhibitor, significantly reduced LDL-C in patients with HoFH in a pivotal Phase 3 trial (NCT03399786). The current study assesses long-term safety and efficacy of evinacumab in patients with HoFH. Methods: This is an interim analysis of an evinacumab open-label Phase 3 trial (NCT03409744) in adult and adolescent(12-<18 years) patients with HoFH. Patients who previously received evinacumab or who were evinacumab-naïve both received intravenous evinacumab 15 mg/kg every 4 weeks. Results: A total of 115 patients (50.4% male; mean [range] age 39 [12-75] years; 11.3% adolescent) were enrolled and treated for a mean (range) duration of 53 (4-132) weeks. At baseline, mean (standard deviation [SD]) LDL-C was 261.8 (160.5) mg/dL; 44 (38.3%) patients were receiving concomitant lipoprotein apheresis. At Week 24, data were available for 81 patients. From baseline to Week 24, evinacumab reduced mean LDL-C for all patients by 43.7% (mean [SD], 133.0 [125.9] mg/dL); mean LDL-C reduction for adult (n=72) and adolescent (n=9) subgroups was 42.6% (mean [SD], 126.7 [127.9] mg/dL) and 52.4% (mean [SD], 183.4 [101.6] mg/dL), respectively. Treatment-emergent adverse events (TEAEs) occurred in 76 (66.1%) patients; one patient reported pregnancy which led to discontinuation of study treatment per protocol. Serious TEAEs were reported by 16 (13.9%) patients; two (1.7%) patients experienced a TEAE resulting in death, none of which were considered related to study treatment. Conclusions: In this large cohort of patients with HoFH, evinacumab markedly reduced LDL-C irrespective of age. Evinacumab was generally well tolerated, and the efficacy and safety of evinacumab was sustained over the long term.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".